Bajaj Healthcare Analyst Review May 2026

This Bajaj Healthcare analyst review for May 2026 covers the key data investors need for BAJAJHCARE at its current price of Rs 715. Bajaj Healthcare (NSE: BAJAJHCARE) is a specialty pharmaceutical and API manufacturer with a market capitalisation of approximately Rs 2,500 crore. The analyst consensus target of Rs 850 implies meaningful upside, and this Bajaj Healthcare analyst review examines technical levels, business segments, valuation, and key risks for BAJAJHCARE through FY27.

Click Here – Get Free Investment Predictions

Bajaj Healthcare Company Snapshot May 2026

Bajaj Healthcare manufactures APIs, nutraceuticals, and pharmaceutical intermediates for regulated and domestic markets. Its specialty amino acid and vitamin business serves both pharma and nutraceutical end-markets. The table below summarises the key data referenced in this Bajaj Healthcare analyst review.

Parameter	Value
NSE Ticker	BAJAJHCARE
Sector	Pharmaceuticals – APIs and Specialty
CMP (May 2026)	Rs 715
52 Week High	Rs 1,020
52 Week Low	Rs 620
Market Cap	Rs 2,500 Crore
Trailing P/E	20x
Analyst Consensus Target	Rs 850
Bull Case Target	Rs 1,050
Bear Case Target	Rs 600

Analyst Insight in This Bajaj Healthcare Analyst Review

Associate Director Kunal Singla suggests watching Bajaj Healthcare closely in May 2026. At Rs 715, Kunal Singla flags Pharmaceuticals – APIs and Specialty sector dynamics as the primary driver for BAJAJHCARE’s near-term price action. He notes support in the Rs 632 to Rs 679 zone and flags any sustained close above Rs 758 as a positive signal. Kunal Singla’s perspective on Bajaj Healthcare adds professional analysis to this Bajaj Healthcare analyst review and is not a buy recommendation.

Technical Analysis in This Bajaj Healthcare Analyst Review

At Rs 715, BAJAJHCARE is trading within its 52-week band of Rs 620 to Rs 1,020. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 632 to Rs 679 band while resistance is seen in the Rs 758 to Rs 782 zone. A sustained move above Rs 758 could open the path toward the analyst consensus target of Rs 850 as outlined in this Bajaj Healthcare analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 632 to Rs 679 – investors tracking this Bajaj Healthcare analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for BAJAJHCARE.
• Resistance Zone: Rs 758 to Rs 782 – a sustained close above Rs 758 would be a positive breakout signal worth flagging in this Bajaj Healthcare analyst review.
• Medium-Term Target: The analyst consensus of Rs 850 represents the base-case upside scenario in this Bajaj Healthcare analyst review.

Business Segment Analysis

API and Pharmaceutical Intermediates

This is the primary revenue and margin driver for Bajaj Healthcare, directly supporting the earnings trajectory toward the consensus target of Rs 850.

Nutraceuticals and Amino Acids

This segment adds scale and diversification to Bajaj Healthcare’s business model and is a meaningful EPS contributor through FY27 and FY28.

Specialty Vitamins and Health Ingredients

This represents the medium-term growth frontier for Bajaj Healthcare and a key re-rating catalyst over the next 12 to 24 months.

Valuation in This Bajaj Healthcare Analyst Review

At Rs 715, Bajaj Healthcare trades at a trailing P/E of 20x. This Bajaj Healthcare analyst review presents three scenarios: a bull case of Rs 1,050 on strong earnings delivery and sector tailwinds, a base case of Rs 850 at analyst consensus, and a bear case of Rs 600 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Bajaj Healthcare analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 1,050	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 850	Moderate growth, analyst consensus estimate
Bear Case	Rs 600	Earnings miss or macro headwinds

Trade Outlook for Bajaj Healthcare

Based on the technical and fundamental analysis in this Bajaj Healthcare analyst review, investors might watch BAJAJHCARE near the support zone of Rs 632 to Rs 679 for potential opportunities. A flag above Rs 758 could suggest improving momentum toward Rs 850. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Bajaj Healthcare in FY27

A well-rounded Bajaj Healthcare analyst review must assess downside risks. Key risks for Bajaj Healthcare include a macro slowdown affecting Pharmaceuticals – APIs and Specialty sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in BAJAJHCARE.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Bajaj Healthcare Analyst Review Verdict for 2026

This Bajaj Healthcare analyst review concludes that at Rs 715, BAJAJHCARE offers a defined risk-reward with a consensus target of Rs 850. The 52-week range of Rs 620 to Rs 1,020 provides context on the current entry point. Use this Bajaj Healthcare analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on BAJAJHCARE.

Frequently Asked Questions: Bajaj Healthcare Analyst Review 2026

What is the analyst target for Bajaj Healthcare in 2026?

The analyst consensus target is Rs 850, with a bull case of Rs 1,050 and a bear case of Rs 600. This Bajaj Healthcare analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Bajaj Healthcare a good investment at Rs 715?

At Rs 715 with a P/E of 20x and a consensus target of Rs 850, this Bajaj Healthcare analyst review is constructive for medium to long-term investors in the Pharmaceuticals – APIs and Specialty sector. Always consult a SEBI-registered advisor before investing.

What is Bajaj Healthcare’s 52-week high and low?

The 52-week high is Rs 1,020 and the 52-week low is Rs 620. At Rs 715, BAJAJHCARE is positioned within this range as detailed in this Bajaj Healthcare analyst review.

What are the key risks for Bajaj Healthcare?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – APIs and Specialty sector, all assessed in this Bajaj Healthcare analyst review.

Where can I track live data for Bajaj Healthcare?

Track Bajaj Healthcare’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Bajaj Healthcare analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.